MM-151

MM-151 is an oligoclonal mixture of monoclonal antibodies, which binds multiple parts of the EGFR molecule[1] It has started clinical trials in patients with RAS wild-type colorectal cancers (CRCs) that were resistant to other anti-EGFR therapies.[1] It is intended to overcome the problem of cancers becoming resistant to monoclonal antibody therapies.

Clinical trials

In solid tumours.[2]

In conjunction with MM-121 for various cancers.[3]

Mechanism of action

The mixture of antibodies can bind multiple parts of the EGFR molecule, so the cancer cannot develop resistance by mutating one site at a time.[1]

References

  1. 1 2 3 MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
  2. ↑ Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
  3. ↑ Phase 1 Combination Study of MM-151 and MM-121
This article is issued from Wikipedia - version of the Thursday, February 11, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.